GLP-1 in Ulcerative Colitis: 66.7% vs 25.3% at 12 Weeks

Remission of ulcerative colitis in patients taking GLP-1 receptor agonists was the subject of a matched cohort study published in Inflammatory Bowel Diseases on 21 August 2026. The study followed 150 adults with ulcerative colitis who began a GLP-1 receptor agonist for metabolic indications, matched to 150 similar patients who did not receive the drug. At 12 weeks, 66.7 percent of those on the drugs were in symptomatic remission, compared to 25.3 percent of the controls.

One sentence in the abstract does more work than the headline number. The authors report that weight loss was not associated with remission.

A quick framing note. These are approved drugs and this is a study of patients. Nothing here is guidance about human use, and the research peptides discussed later are supplied for laboratory work only.

Constructing the GLP-1 cohort

This study comes from West Virginia University and uses electronic health records from a single tertiary academic health system from 2022 to 2024. Patients were eligible if they were adults with ulcerative colitis who initiated liraglutide or semaglutide for a metabolic indication and were treated at least 12 weeks. Each patient was individually matched to a patient with ulcerative colitis who was not treated with either of these drugs. The primary outcome was symptomatic remission at 12 weeks, defined as a partial Mayo score of 2 or less with a rectal bleeding subscore of zero.

The partial Mayo score is worth unpacking briefly. It is the sum of stool frequency, rectal bleeding and the global assessment of disease by the physician. The requirement that the rectal bleeding subscore be exactly zero means that any patient with visible blood is not counted as in remission, regardless of the other subscores. It is a higher bar than a simple sum score threshold.

Results for the GLP-1 cohort

The mean partial Mayo score dropped from 5.8 at baseline to 2.1 at 12 weeks in the GLP-1 group, versus 4.6 in controls. The adjusted odds ratio for remission was 5.90, with a confidence interval of 3.52 to 9.86.

In the endoscopic subset, remission was 58 percent versus 38 percent and improvement was 69 percent versus 47 percent. Endoscopic readouts matter more than symptom scores here, because a patient can feel better but still have inflamed mucosa, and the gap between those two states is where a lot of colitis research goes wrong.

Semaglutide did better than liraglutide, 72.5 percent versus 60 percent, odds ratio 1.77. That is a difference within the class, not a GLP-1 class effect.

The dissociation, part three this month

An odds ratio of 5.90 in a GLP-1 database study should make any reader skeptical, and the obvious suspicion is that the drug is not doing this at all. The natural confounder here is weight. People who lose a lot of weight feel better, are more active, change what they eat, and report fewer symptoms.

The authors investigated and report that weight loss was not associated with remission.

This is the third study in a month where a GLP-1 paper dissociates the outcome from weight loss. The prespecified analysis of the SELECT trial found the inflammatory marker dropped before weight did. A matched liver cohort found tirzepatide dropped more BMI than semaglutide and delivered the same hard liver outcomes. This colitis study finds remission does not correlate with weight either.

Three organs, three studies, one pattern. This does not prove a weight independent anti-inflammatory mechanism, but it does mean people still explaining every GLP-1 result by weight loss are running out of space.

What this GLP-1 cohort cannot determine

Four limits, and the first two are the serious ones.

A single health system, 300 patients. One tertiary centre means one centre with its own referral patterns, its own GLP-1 prescribing culture and its own coding habits. An odds ratio of 5.90 from 300 patients at one health system is a signal to replicate, not a finding to build on.

Matched does not mean randomised. There are differences between patients who begin a GLP-1 agonist and those who do not that reach well beyond the matched variables: insurance status, engagement with the healthcare system, severity of disease at the time of the decision, and whether the gastroenterologist believed the patient was stable enough to begin a drug for a metabolic indication. The last one alone could account for a lot of this result.

Symptomatic remission is partly a consequence of the drug’s effect on the gut. GLP-1 receptor agonists slow gastric emptying and alter stool frequency. Two of the three components that make up the partial Mayo score are symptom counts. A drug that alters bowel habit will move the score without affecting mucosal inflammation. This is why the endoscopic subset is the more informative half of the paper.

Twelve weeks is a short follow up for a relapsing and remitting disease.

A better designed study asking the same question already exists. An emulation of a target trial published in Clinical Gastroenterology and Hepatology in June 2026 looked at the use of adjunctive GLP-1 receptor agonists in inflammatory bowel disease with obesity or diabetes. It is best to read the two studies together rather than separately.

Why this paper is close to the peptide catalogue

Intestinal inflammation is one of the few areas where a research peptide has a genuinely deep preclinical literature, and it is worth setting the two next to each other.

KPV is the C-terminal tripeptide of alpha-MSH. A 2007 paper in Gastroenterology found that KPV was taken up via the intestinal peptide transporter PepT1 and reduced intestinal inflammation. Since then, the PepT1 route has been worked on continuously. That is a mechanistically specific claim about the gut made almost 20 years ago, and it is a type of evidence different from a 300 patient database study. Neither substitutes for the other. We wrote about the same tripeptide in an adipocyte model earlier this month, and the research reference hub collects what the published record holds.

TB-500 is the synthetic fragment of thymosin beta-4. The parent protein has its own colitis literature. We wrote about a 2026 mouse study on thymosin beta-4 in colitis that linked it to a receptor no-one had previously associated with the peptide.

Neither compound is what this cohort study examined, and neither has anything resembling a controlled trial in colitis. The comparison being made is the other way around. The GLP-1 drugs with the clinical data have the weaker mechanistic story in the gut, and the peptides with the mechanistic story have no clinical data. Those two gaps face each other.

Finally, worth noting that tirzepatide and retatrutide were not in this study at all. It tested liraglutide and semaglutide, the two oldest agents in the class.

For laboratories, our European research buyer guide covers procurement, and everything is supplied on a research use only basis.

References

• Alqinai B, Gayam S, Hadam-Veverka J. GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study. Inflammatory Bowel Diseases, 21 August 2026. doi 10.1093/ibd/izag167
• Yeh KH, Ahuja D, Patel SB, Xu R. Adjunctive GLP1 Receptor Agonists in Patients With Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation. Clinical Gastroenterology and Hepatology, 17 June 2026
• Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 17 October 2007
• Zhao TR, Hu EB, Wang MW, Zhai YF, et al. Recombinant human Thymosin beta-4 ameliorates experimental colitis and intestinal fibrosis through suppression of mineralocorticoid receptor. Molecular Biomedicine, 17 August 2026

The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.